REG - Tissue Regenix Group - Exercise of Options and Total Voting Rights

Tissue RegenixAnnouncement

31/08/2023 13:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230831:nRSe9962Ka&default-theme=true

RNS Number : 9962K  Tissue Regenix Group PLC  31 August 2023

 

Tissue Regenix Group plc

('Tissue Regenix', the 'Company' or the 'Group')

 

Exercise of Options

And Total Voting Rights

 

Tissue Regenix Group (AIM:TRX), the regenerative medical devices company,
announces that it has received notification for the exercise of options to
subscribe for 216,519 new ordinary shares in the Company ("Ordinary Shares")
at an exercise price of 27.6 pence per Ordinary Share. These shares are being
issued pursuant to an exercise of options under the 2020 Tissue Regenix Group
plc SAYE Option Plan.

 

The above number includes 65,217 Ordinary Shares issued to Kirsten Lund, a
PDMR of the Company. Following the issue, Kirsten will hold 65,217 Ordinary
Shares, representing 0.09% of the Company's issued share capital.

 

The 216,519  new Ordinary Shares will rank pari passu with the existing
Ordinary Shares and application has been made for these new Ordinary Shares to
be admitted to trading on AIM. It is expected that admission will occur at
8:00 a.m. on 6 September 2023.

 

Total Voting Rights

Following the issue of the 216,519 new Ordinary Shares, the Company will have
a total of 70,574,468 Ordinary Shares in issue. The above figure may be used
by shareholders in the Company as the denominator for the calculations by
which they will determine if they are required to notify their interest in, or
a change in their interest in, the share capital of the Company under the
FCA's Disclosure and Transparency Rules.

 

 

For more information:

 

 Tissue Regenix Group plc                                                 www.tissueregenix.com (http://www.tissueregenix.com)
 Daniel Lee, Chief Executive Officer                                      Via Walbrook PR

 finnCap Ltd (Nominated Adviser and Broker)
 Emily Watts/Geoff Nash/George Dollemore - Corporate Finance
 Nigel Birks/Harriet Ward - ECM

 Walbrook PR (Financial PR & IR)      Tel: +44(0)20 7933 8780
 Alice Woodings/Lianne Applegarth     TissueRegenix@walbrookpr.com (mailto:TissueRegenix@walbrookpr.com)

 

About Tissue Regenix (www.tissueregenix.com)

Tissue Regenix is a leading medical device company in the field of
regenerative medicine. The Company's patented decellularisation technology
('dCELL®') removes DNA and other cellular material from animal and human soft
tissue, leaving an acellular tissue scaffold that is not rejected by the
patient's body and can then be used to repair diseased or damaged body
structures. Current applications address many critical clinical needs in
sports medicine, foot and ankle and wound care.

 

In August 2017, Tissue Regenix acquired CellRight Technologies®, a biotech
company that specialises in regenerative medicine and is dedicated to the
development of high-quality, innovative tissue scaffolds, which can enhance
healing opportunities in defects created by trauma and disease. CellRight's
human tissue products may be used in spine, trauma, general orthopaedic,
dental and ophthalmological surgical procedures.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOESDMFEFEDSEDA